Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial

Michele Maio, Arnaud Scherpereel, Luana Calabrò, Joachim Aerts, Susana Cedres Perez, Alessandra Bearz, Kristiaan Nackaerts, Dean A. Fennell, Dariusz Kowalski, Anne S. Tsao, Paul Taylor, Federica Grosso, Scott J. Antonia, Anna K. Nowak, Maria Taboada, Martina Puglisi, Paul K. Stockman, Hedy L. Kindler

Research output: Contribution to journal › Article › peer-review

252 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial'. Together they form a unique fingerprint.

Medicine & Life Sciences